Routine investigations, including complete hemogram, serum biochemistry, and urinalysis of both patients, were within normal limits. Based on the clinical features and histopathological examination, a diagnosis of PRIDE complex was made in both cases. On the basis of National Cancer Institute-Common Terminology Criteria for Adverse Events v 4.02 Grading of PRIDE complex, [6] our first case diagnosed as Grade 2 and the second case as Grade 1 type of PRIDE complex [ Table 1 ]. Since the clinical features were mild, so treatment of both the patients was continued with EGFR inhibitor. Both the patients were treated with benzoyl peroxide 2.5% wash and doxycycline 100 mg BD for 2 weeks. Xerosis was treated with regular application of emollients. Both patients showed excellent response in the form of resolution of all lesions within 2 weeks of treatment [ Figure 4a -d]. Pre treatment and post treatment comparative photos of case 2 can be seen in Figure 5a -b. No improvement in hair loss was observed in the first patient. discussion EGFR are used for malignancies which include metastatic nonsmall cell lung cancer, colorectal cancer, pancreatic cancer, and squamous cell carcinoma of the head and neck. Corneocytes of the basal layer, sweat glands, and hair follicles largely express EGFR. [1, 7] Normal functions of the skin are inhibited which causes cutaneous adverse effects. [1, 6] Incidence of these cutaneous adverse events from EGFR inhibitors was found to be 68.7%-80% of patients. [3, 8] Various precipitating factors for these cutaneous adverse effects are sun exposure, concomitant radiotherapy, and inadequate moisture levels in the skin. [9] Chanprapaph et al. reported the onset of adverse effect ranged from 8 days to 15 weeks after treatment with EGFR inhibitors and the earliest cutaneous adverse event was papulopustular eruption (PPE), for which the median latent period was 13 days (range 8-25 days). [3] The most common adverse event is xerosis, followed by PPE. [3] Less common adverse events reported were maculopapular rash, mucositis, paronychia, and trichomegaly of the eyelashes, telangiectasia, and hyperpigmentation. [4, [7] [8] [9] [10] Severe xerosis with mucosal involvement can sometimes lead to sicca-like syndrome.
[10] Cutaneous adverse events have been observed with all agents that target EGFR and therefore considered a class-specific effect, and the frequency and severity of skin rashes are dose dependent. [10] Some authors stated that the presence and intensity of a PPE have a positive correlation with the effectiveness of the therapy, suggesting a gradual increase in dose until a severe PPE is produced("dose to rash). [11] The acronym "PRIDE" is used for constellation of cutaneous side effects which include papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to EGFR inhibition. Pathogenesis and treatment of PRIDE complex is depicted in Table 2 . [4, 8, 9, 12] The PPE s usually arises a few days after treatment with the EGFR inhibitor, to reach a maximum after 2-3 weeks. More rarely (11%), the rash occurs in a delayed fashion after the first 3 weeks of treatment with cetuximab. [2] These lesions are more pruritic, erythematous, and more inflammatory as compared to other drug-induced acneiform eruptions. [2, 3, 9] The eruption is more or less confined to the seborrheic areas such as the face, neck and retroauricular area, the shoulders, V-shaped area of the upper trunk, and the scalp. [13] The lower parts of the back, the abdomen, the buttocks, and even the arms and legs can be rarely involved as well, whereas the palms and soles are spared. [3, 11, 13] Incidence of PPE was reported to be 27.3%-86% from previous studies. [3, 14] The classical presentation of PPE is inflamed papules or pustules with hair at the center. [3] In histopathology, acneiform lesions show a picture of a florid superficial suppurative folliculitis, i.e., neutrophilic folliculitis and perifolliculitis. [10, 15] PPEs and xerosis were more commonly reported with erlotinib than with gefitinib. [3, 8] Our first case had PPE s in the seborrheic area along with involvement of abdomen and lower limbs with xerosis in patient of nonsmall cell carcinoma of the lung, after 6 weeks of initiation of therapy with gefitinib. Our second case had similar rash over the lower limbs with less involvement of seborrheic areas with xerosis after 2 weeks of commencement of therapy with erlotinib in case of nonsmall cell carcinoma of the lung. Nail and hair abnormalities attributable to EGFR inhibitors were not observed in both of our patients. No systemic toxicities were present in both the cases. Both the patients had significant relief of symptoms after 2 weeks treatment with oral doxycycline, topical benzoyl peroxide, and emollients. Oral retinoids have same adverse effects as with EGFR inhibitor i.e., xerosis and paronychia therefore they should be avoided for treatment of papulopustular eruptions. [10] Prophylactically, the patient should be informed about cutaneous side effects and should be advised to mild soap, take quick showers with warm water, and repeated and regular use of emollients preferably all over the skin and with products containing no alcohol or perfume. [16] It is important for clinicians to be aware of this condition, as it can be treated symptomatically without discontinuation of drug. We report two cases of PRIDE complex because of its rarity in presentation.
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